Indication
Prevention of CMV disease in advanced HIV patient
Prevention of cytomegalovirus (CMV) disease in advanced HIV patients refers to prophylactic and risk-reduction strategies directed against opportunistic reactivations of human cytomegalovirus in individuals with profound retroviral-mediated immunosuppression, typically defined by CD4 T-lymphocyte counts below 50 to 100 cells/mm³. Read more about Prevention of CMV disease in advanced HIV patient
0 drugs 0 manufacturers
Drugs that treat it
Common Prevention of CMV disease in advanced HIV patient therapies.
No drugs are available
This indication does not currently contain public drugs.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonPrevention of cytomegalovirus (CMV) disease in advanced HIV patients refers to prophylactic and risk-reduction strategies directed against opportunistic reactivations of human cytomegalovirus in individuals with profound retroviral-mediated immunosuppression, typically defined by CD4 T-lymphocyte counts below 50 to 100 cells/mm³.
Due to impaired cell-mediated immunity, latent CMV reactivates and causes life- or sight-threatening end-organ pathology, most commonly necrotizing retinitis, as well as gastrointestinal ulcerations, encephalitis, or polyradiculopathy.
Prophylactic strategies aim to suppress viral replication, avert irreversible tissue necrosis, and forestall blindness or systemic mortality in this severely compromised patient population.
- hiv.gov
Prevention of cytomegalovirus (CMV) disease in advanced HIV patients refers to prophylactic and risk-reduction strategies directed against opportunistic reactivations of human cytomegalovirus in individuals with profound retroviral-mediated immunosuppression, typically defined by CD4 T-lymphocyte counts below 50 to 100 cells/mm³
- iapac.org
Prevention of cytomegalovirus (CMV) disease in advanced HIV patients refers to prophylactic and risk-reduction strategies directed against opportunistic reactivations of human cytomegalovirus in individuals with profound retroviral-mediated immunosuppression, typically defined by CD4 T-lymphocyte counts below 50 to 100 cells/mm³ Due to impaired cell-mediated immunity, latent CMV reactivates and causes life- or sight-threatening end-organ pathology, most commonly necrotizing retinitis, as well as...
- cdc.gov
Due to impaired cell-mediated immunity, latent CMV reactivates and causes life- or sight-threatening end-organ pathology, most commonly necrotizing retinitis, as well as gastrointestinal ulcerations, encephalitis, or polyradiculopathy
- webmd.com
Due to impaired cell-mediated immunity, latent CMV reactivates and causes life- or sight-threatening end-organ pathology, most commonly necrotizing retinitis, as well as gastrointestinal ulcerations, encephalitis, or polyradiculopathy Prophylactic strategies aim to suppress viral replication, avert irreversible tissue necrosis, and forestall blindness or systemic mortality in this severely compromised patient population
- nih.gov
Prophylactic strategies aim to suppress viral replication, avert irreversible tissue necrosis, and forestall blindness or systemic mortality in this severely compromised patient population
Personalize your experience
Follow Prevention of CMV disease in advanced HIV patient and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.